Radiopharmaceuticals are no longer an emerging promise; they are becoming a defining force in oncology. Targeted radiopharmaceutical therapies are rapidly gaining prominence as one of the most promising approaches to precision cancer treatment.

Momentum across the sector is undeniable. Breakthrough therapies continue to advance through the clinic, alpha‑emitting isotopes are unlocking new possibilities for highly potent tumour targeting, and the theranostic paradigm is redefining how patients are diagnosed and treated. As more assets progress into late‑stage trials and combination strategies gain traction, radiopharmaceuticals are positioned to play a central role in the next generation of oncology therapeutics.

Yet with this rapid growth comes a unique and complex set of challenges. Unlike traditional drug modalities, radiopharmaceutical development requires a tightly integrated ecosystem spanning radiochemistry, isotope production, specialized clinical sites, manufacturing infrastructure, and regulatory expertise.

This is why the 5th Targeted Radiopharmaceuticals Summit US returns in 2026 as the industry’s most comprehensive end-to-end meeting dedicated to advancing radioligand therapies from discovery through to commercialization. Over three focused days, gain practical insight into how leading organizations are solving the scientific, clinical, manufacturing, and supply challenges that define success in this space.

View the event here.